bisoprolol has been researched along with pindolol in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (20.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 4 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; el Tayar, N; Testa, B; Van de Waterbeemd, H | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Carrupt, PA; Guillarme, D; Henchoz, Y; Rudaz, S; Veuthey, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bard, B; Carrupt, PA; Martel, S | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Müller, RK; Tarnow, J | 1 |
| Brodde, OE; Deighton, NM; Khamssi, M; Motomura, S; Zerkowski, HR | 1 |
| Brodde, OE | 1 |
| Borchard, U; Brinkmann, M; Brodde, OE; Daul, A; Schemuth, R; Wang, XL | 1 |
| Görtelmeyer, R; Klingmann, I | 1 |
| Böhm, M; Emslander, HP; Hauck, RW; Schulz, C | 1 |
| Sal'nikov, EV | 1 |
| Abdelkrim, MA; Chatagnon, G; Desfontis, JC; Gogny, M; Mallem, MY; Noireaud, J | 1 |
2 review(s) available for bisoprolol and pindolol
| Article | Year |
|---|---|
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Models, Molecular; Receptors, Adrenergic, beta; Structure-Activity Relationship | 1988 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for bisoprolol and pindolol
| Article | Year |
|---|---|
[Comparative study of the central nervous system effect of the beta receptor blockaders pindolol and bisoprolol].
Topics: Adult; Bisoprolol; Blood Pressure; Central Nervous System; Double-Blind Method; Emotions; Heart Rate; Humans; Male; Middle Aged; Pindolol; Propanolamines; Random Allocation; Sleep; Time Factors; Tremor | 1985 |
17 other study(ies) available for bisoprolol and pindolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.
Topics: Chemical Phenomena; Chemistry, Pharmaceutical; Chemistry, Physical; Chromatography, Liquid; Mathematics; Pharmaceutical Preparations; Software | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
Topics: Chemistry, Pharmaceutical; Chromatography; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Pharmaceutical Preparations; Solubility; Technology, Pharmaceutical | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Cardiovascular effect of low-dose epinephrine infusions in relation to the extent of preoperative beta-adrenoceptor blockade.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Epinephrine; Hemodynamics; Humans; Metoprolol; Middle Aged; Myocardial Revascularization; Pindolol; Preoperative Care; Propanolamines | 1991 |
Differential regulation of human cardiac beta-adrenergic and muscarinic receptors by chronic beta-adrenoceptor antagonist treatment.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Bisoprolol; Electric Stimulation; Humans; In Vitro Techniques; Iodocyanopindolol; Metoprolol; Middle Aged; Myocardial Contraction; Myocardium; N-Methylscopolamine; Parasympatholytics; Pindolol; Propanolamines; Receptors, Adrenergic, beta; Receptors, Muscarinic; Scopolamine Derivatives | 1990 |
Bisoprolol (EMD 33512), a highly selective beta 1-adrenoceptor antagonist: in vitro and in vivo studies.
Topics: Adrenergic beta-Antagonists; Animals; Bisoprolol; Isoproterenol; Lung; Lymphocytes; Membranes; Pindolol; Propanolamines; Propranolol; Rabbits; Receptors, Adrenergic, beta; Renin; Sympathomimetics | 1986 |
Beta-adrenoceptor antagonists (non-selective as well as beta 1-selective) with partial agonistic activity decrease beta 2-adrenoceptor density in human lymphocytes. Evidence for a beta 2-agonistic component of the partial agonistic activity.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Bisoprolol; Blood Pressure; Celiprolol; Cyclic AMP; Female; Heart Rate; Humans; Isoproterenol; Kinetics; Lymphocytes; Male; Middle Aged; Pindolol; Propanolamines; Receptors, Adrenergic, beta | 1986 |
Pharmacological actions of the selective and non-selective beta-adrenoceptor antagonists celiprolol, bisoprolol and propranolol on human bronchi.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Bronchi; Celiprolol; Dose-Response Relationship, Drug; Female; Guanylyl Imidodiphosphate; Heart; Humans; Male; Middle Aged; Pindolol; Propranolol | 1994 |
Heart rate variability in rats with experimental chronic heart failure and long-term exposure to beta-adrenoblockers.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Benzopyrans; Bisoprolol; Ethanolamines; Heart Failure; Heart Rate; Male; Metoprolol; Nebivolol; Pindolol; Propranolol; Rats | 2009 |
Autoantibodies against cardiac β(1)-adrenoceptor do not affect the low-affinity state β(1)-adrenoceptor-mediated inotropy in rat cardiomyocytes.
Topics: 1-Methyl-3-isobutylxanthine; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-1 Receptor Antagonists; Animals; Autoantibodies; Bisoprolol; Isoproterenol; Male; Myocardial Contraction; Myocytes, Cardiac; Phosphodiesterase Inhibitors; Pindolol; Propanolamines; Propranolol; Rats; Rats, Wistar; Receptors, Adrenergic, beta-1 | 2012 |